Elanco Animal Health (NYSE:ELAN) Stock Price Breaks Above 200-Day Moving Average – Time to Sell?

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) passed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $23.82 and traded as high as $26.26. Elanco Animal Health shares last traded at $25.6460, with a volume of 11,505,379 shares traded.

Key Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS was $0.27, ahead of the $0.20 consensus, while revenue rose 11% year over year to $1.265 billion, topping estimates. Elanco also reported 9% organic constant-currency growth and gross-margin expansion. Read More.
• Positive Sentiment: Elanco raised its 2026 adjusted EPS outlook to $1.17–$1.20, versus the $1.13 consensus, and revenue guidance to $5.155–$5.18 billion, above the $5.1 billion consensus. It also lifted its innovation revenue target and improved its year-end net-leverage target to about 2.9x adjusted EBITDA. Read More.
• Positive Sentiment: Company survey findings offered further demand support: 93% of pet owners surveyed said they maintained or increased pet spending in the prior three months despite cost pressures. Read More.
• Neutral Sentiment: Fourth-quarter adjusted EPS guidance of $0.16–$0.19 brackets the $0.18 consensus, while revenue guidance of $1.2 billion matches estimates. Elanco’s early 2027 outlook calls for growth broadly in line with its previously stated long-term targets, rather than a further acceleration. Read More.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ELAN. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Jefferies Financial Group lowered shares of Elanco Animal Health from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $31.00 to $24.00 in a report on Tuesday, October 20th. Morgan Stanley dropped their target price on shares of Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating for the company in a research report on Thursday, October 29th. The Goldman Sachs Group initiated coverage on shares of Elanco Animal Health in a research report on Friday, October 16th. They issued a “buy” rating and a $32.00 target price for the company. Finally, UBS Group lifted their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.33.

Elanco Animal Health Stock Performance

The stock has a market capitalization of $12.81 billion, a PE ratio of -85.48, a PEG ratio of 2.28 and a beta of 1.73. The business has a 50 day moving average price of $23.13 and a 200 day moving average price of $23.82. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Friday, November 6th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.07. The firm had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.21 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. Elanco Animal Health’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.19 EPS. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. As a group, equities research analysts expect that Elanco Animal Health Incorporated will post 1.13 earnings per share for the current year.

Insider Activity

In other news, Director Lawrence Kurzius purchased 40,000 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were purchased at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the acquisition, the director directly owned 188,647 shares in the company, valued at $4,414,339.80. This represents a 26.91% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Timothy J. Bettington sold 4,350 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $23.00, for a total transaction of $100,050.00. Following the sale, the insider directly owned 138,911 shares of the company’s stock, valued at $3,194,953. This trade represents a 3.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have bought 48,998 shares of company stock worth $1,139,373. Corporate insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELAN. Eurizon Capital SGR S.p.A. increased its holdings in shares of Elanco Animal Health by 139.8% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 92,821 shares of the company’s stock worth $2,080,000 after purchasing an additional 54,111 shares in the last quarter. Maryland State Retirement & Pension System raised its stake in shares of Elanco Animal Health by 17.1% in the third quarter. Maryland State Retirement & Pension System now owns 30,363 shares of the company’s stock worth $680,000 after purchasing an additional 4,442 shares during the last quarter. Ritholtz Wealth Management lifted its holdings in shares of Elanco Animal Health by 5.0% during the third quarter. Ritholtz Wealth Management now owns 9,335 shares of the company’s stock valued at $209,000 after purchasing an additional 446 shares in the last quarter. New York Life Investment Management LLC lifted its holdings in shares of Elanco Animal Health by 17.7% during the third quarter. New York Life Investment Management LLC now owns 72,257 shares of the company’s stock valued at $1,618,000 after purchasing an additional 10,853 shares in the last quarter. Finally, AlphaCore Capital LLC lifted its holdings in shares of Elanco Animal Health by 16.5% during the third quarter. AlphaCore Capital LLC now owns 21,139 shares of the company’s stock valued at $473,000 after purchasing an additional 2,989 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health.

For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

The company traces its origins to Eli Lilly’s animal health business, established in 1954, and became an independent public company in 2018.